. 2022 Feb 18;53:12. doi: 10.1186/s13567-022-01029-w

Table 10.

T cell epitope content comparison (EpiCC) analysis

Treatment Group (T) and description			EpiCC scores		Percent coverage		% Improvement of homologous vs heterologous coverage ^a
	Vaccine	Challenge	PCV2a ORF2 ^b	PCV2b ORF2 ^c	PCV2a ORF2 ^b	PCV2b ORF2 ^c	% Improvement of homologous vs heterologous coverage ^a
T02 homologous treatment	cPCV2a	PCV2a	10.42 ^d	7.51	100.00	72.05	36.46
T04 heterologous treatment	cPCV2a	PCV2b	7.51	10.25 ^d	73.28	100.00	36.46

^a The percent improvement of homologous (cPCV2a vaccine, PCV2a challenge) versus heterologous (cPCV2a vaccine, PCV2b challenge) coverage (|(heterologous-homologous)|/heterologous * 100%) representing the situation in Study A.

^b Situation tested in studies A and B.

^c Situation tested in study C.

^d Represents baseline where the challenge strain is identical to the vaccine strain.